Drug Profile
Transbuccal insulin - MidaSol
Alternative Names: Insulin - MidaSol; Insulin buccal soluble film - Biodexa Pharmaceuticals; Insulin nanoparticles buccal film - Midasol; MidaForm insulin PharmFilm; MidaForm™-Insulin-Pharmfilm®; MSL-001; MSRX-301; MTD-101; Nanoparticle insulinLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator MidaSol Therapeutics; Midatech; MonoSol Rx
- Developer MidaSol Therapeutics
- Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 03 Dec 2018 Discontinued - Phase-II for Type 1 diabetes mellitus in Australia (Buccal)
- 27 Jul 2015 Phase-II clinical trials in Type-1 diabetes mellitus in Australia (Buccal) (ACTRN12615000495527)
- 01 Jul 2015 Midatech and Monosol plan a phase II trial Type-I diabetes mellitus in Australia (ACTRN12615000495527)